Is ramucirumab still the only second-line treatment in metastatic gastric cancer?

2020 ◽  
Vol 21 (17) ◽  
pp. 1203-1206
Author(s):  
Khalil El Gharib ◽  
Hampig Raphael Kourie
Keyword(s):  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line

An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS4131-TPS4131 ◽  
Author(s):  
Tomohiro Nishina ◽  
Shuichi Hironaka ◽  
Shigenori Kadowaki ◽  
Takeharu Yamanaka ◽  
Takako Eguchi Nakajima
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Multicenter Phase

scholarly journals Real-world evidence: A review of clinical experience in metastatic gastric cancer second-line treatment with ramucirumab

2019 ◽  
Vol 16 (3) ◽  
Author(s):  
Miguel Quintana-Quintana ◽  
María Consuelo Díaz-Romero ◽  
Christian Patricio Camacho-Limas ◽  
Laura Torrecillas-Torres ◽  
Erika Ruiz-García ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Experience ◽  
Real World ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Real World Evidence

scholarly journals Not only chemotherapy in the second-line treatment of metastatic gastric cancer

2014 ◽  
Vol 25 (2) ◽  
pp. 544-545 ◽  
Author(s):  
E. Vasile ◽  
C. Caparello ◽  
S. Caponi ◽  
L. Ginocchi ◽  
C. Vivaldi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line

scholarly journals P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study

2020 ◽  
Vol 31 ◽  
pp. S176-S177
Author(s):  
A. Michelotti ◽  
E. Ongaro ◽  
L. Gerratana ◽  
M. De Scordilli ◽  
P. Di Nardo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
Second Line
Sign in / Sign up

Export Citation Format

Share Document